Europe Age-Related Macular Degeneration (AMD) Disease Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET 26
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 TYPE LIFELINE CURVE 37
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.9 DBMR MARKET POSITION GRID 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PESTEL 47
4.2 PORTER'S FIVE FORCES MODEL 48
5 REGULATORY FRAMEWORK 49
6 MARKET OVERVIEW 52
6.1 DRIVERS 54
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 54
6.1.2 INCREASING GERIATRIC POPULATION 54
6.1.3 INCREASE IN PIPELINE PRODUCTS 55
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 56
6.2 RESTRAINTS 56
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 56
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 57
6.3 OPPORTUNITIES 58
6.3.1 INCREASING RESEARCH AND DEVELOPMENT 58
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 58
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 59
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 59
6.4 CHALLENGES 60
6.4.1 LIMITED ACCESS TO TREATMENT 60
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 60
7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE 61
7.1 OVERVIEW 62
7.2 DRY AMD 65
7.3 WET AMD 65
7.3.1 MEDICATIONS 66
7.3.2 ANTI-VEGF THERAPY 67
7.3.3 GENE THERAPY 67
7.3.4 SURGERY 67
8 EUROPE AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER 68
8.1 OVERVIEW 69
8.2 HOSPITALS 72
8.3 SPECIALTY CLINICS 72
8.4 AMBULATORY SURGICAL CENTERS 73
8.5 HOME HEALTHCARE 74
8.6 OTHERS 75
9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 76
9.1 OVERVIEW 77
9.2 RETAIL SALES 81
9.2.1 HOSPITAL PHARMACIES 82
9.2.2 RETAIL PHARMACIES 82
9.2.3 OTHERS 82
9.3 DIRECT TENDER 82

10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION 83
10.1 EUROPE 84
10.1.1 GERMANY 90
10.1.2 FRANCE 92
10.1.3 U.K. 94
10.1.4 RUSSIA 96
10.1.5 ITALY 98
10.1.6 SPAIN 100
10.1.7 NETHERLANDS 102
10.1.8 SWITZERLAND 104
10.1.9 POLAND 106
10.1.10 TURKEY 108
10.1.11 AUSTRIA 110
10.1.12 HUNGARY 112
10.1.13 NORWAY 114
10.1.14 IRELAND 116
10.1.15 LITHUANIA 118
10.1.16 REST OF EUROPE 120
11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE 121
11.1 COMPANY SHARE ANALYSIS: EUROPE 121
12 SWOT ANALYSIS 122
13 COMPANY PROFILE 123
13.1 NOVARTIS AG 123
13.1.1 COMPANY SNAPSHOT 123
13.1.2 REVENUE ANALYSIS 123
13.1.3 COMPANY SHARE ANALYSIS 124
13.1.4 PRODUCT PORTFOLIO 124
13.1.5 RECENT DEVELOPMENT 124
13.1.5.1 AGREEMENT 124
13.2 GENENTECH, INC. 125
13.2.1 COMPANY SNAPSHOT 125
13.2.2 COMPANY SHARE ANALYSIS 125
13.2.3 PRODUCT PORTFOLIO 126
13.2.4 RECENT DEVELOPMENT 126

13.3 BAYER AG 127
13.3.1 COMPANY SNAPSHOT 127
13.3.2 REVENUE ANALYSIS 127
13.3.3 COMPANY SHARE ANALYSIS 128
13.3.4 PRODUCT PORTFOLIO 128
13.3.5 RECENT DEVELOPMENT 128
13.4 ADVERUM BIOTECHNOLOGIES, INC. 129
13.4.1 COMPANY SNAPSHOT 129
13.4.2 REVENUE ANALYSIS 129
13.4.3 PRODUCT PORTFOLIO 129
13.4.4 RECENT DEVELOPMENT 130
13.5 ASTELLAS PHARMA INC. 131
13.5.1 COMPANY SNAPSHOT 131
13.5.2 REVENUE ANALYSIS 131
13.5.3 PRODUCT PORTFOLIO 132
13.5.4 RECENT DEVELOPMENT 132
13.6 GRAYBUG VISION INC. 133
13.6.1 COMPANY SNAPSHOT 133
13.6.2 REVENUE ANALYSIS 133
13.6.3 PRODUCT PORTFOLIO 133
13.6.4 RECENT DEVELOPMENT 134
13.7 GENSIGHT BIOLOGICS 135
13.7.1 COMPANY SNAPSHOT 135
13.7.2 REVENUE ANALYSIS 135
13.7.3 PRODUCT PORTFOLIO 136
13.7.4 RECENT DEVELOPMENTS 136
13.7.4.1 EVENT 136
13.7.4.2 AWARD 136
13.8 IONIS PHARMACEUTICALS 137
13.8.1 COMPANY SNAPSHOT 137
13.8.2 REVENUE ANALYSIS 137
13.8.3 PRODUCT PORTFOLIO 138
13.8.4 RECENT DEVELOPMENT 138
13.8.4.1 EVENT 138
13.9 IVERIC BIO 139
13.9.1 COMPANY SNAPSHOT 139
13.9.2 PRODUCT PORTFOLIO 139
13.9.3 RECENT DEVELOPMENT 139

13.10 JOHNSON &JOHNSON SERVICES, INC. 140
13.10.1 COMPANY SNAPSHOT 140
13.10.2 REVENUE ANALYSIS 140
13.10.3 PRODUCT PORTFOLIO 141
13.10.4 RECENT DEVELOPMENT 141
13.10.4.1 COLLABORATION 141
13.11 KODIAK SCIENCES INC. 142
13.11.1 COMPANY SNAPSHOT 142
13.11.2 PRODUCT PORTFOLIO 142
13.11.3 RECENT DEVELOPMENT 142
13.12 MEIRAGTX LIMITED 143
13.12.1 COMPANY SNAPSHOT 143
13.12.2 PRODUCT PORTFOLIO 143
13.12.3 RECENT DEVELOPMENTS 143
13.12.3.1 EVENTS 143
13.12.3.2 AWARD 144
13.12.3.3 COLLABORATION 144
13.13 OCUGEN INC. 145
13.13.1 COMPANY SNAPSHOT 145
13.13.2 PRODUCT PORTFOLIO 145
13.13.3 RECENT DEVELOPMENTS 145
13.13.3.1 INVESTMENT 145
13.13.3.2 CLINICAL TRIAL 146
13.14 PIXIUM VISION 147
13.14.1 COMPANY SNAPSHOT 147
13.14.2 REVENUE ANALYSIS 147
13.14.3 PRODUCT PORTFOLIO 147
13.14.4 RECENT DEVELOPMENT 148
13.14.4.1 AWARD 148
13.15 REGENXBIO INC. 149
13.15.1 COMPANY SNAPSHOT 149
13.15.2 PRODUCT PORTFOLIO 149
13.15.3 RECENT DEVELOPMENTS 149
13.15.3.1 EVENT 149
13.15.3.2 COLLABORATION 150
13.15.3.3 CERTIFICATION 150
14 QUESTIONNAIRE 151
15 RELATED REPORTS 154